UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

———————

FORM 10-Q

———————

X	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
	ACT OF 1934
For the quarterly period ended: September 30, 2010 or
	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
	ACT OF 1934
For the transition period from: _____________ to _____________

———————

XenaCare Holdings, Inc.

(Exact name of registrant as specified in its charter)

———————

Florida	000-53916	20-3075747
(State or other jurisdiction  of incorporation or organization)	Commission  File Number	(I.R.S. Employer  Identification No.)

6001 Broken Sound Parkway, Suite 630

Boca Raton, Florida 33487

(Address of Principal Executive Office) (Zip Code)

(561) 496-6676

(Registrant’s telephone number, including area code)

———————

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the  Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.			X	Yes		No
Indicate by check mark whether the registrant has submitted electronically and posted on its Corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12
months (or for such shorter period that the registrant was required to submit and post such files).				Yes	X	No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.
Large accelerated filer		Accelerated filer
Non-accelerated filer	(Do not check if a smaller	Smaller reporting company			X
	reporting company)
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
				Yes	X	No
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date. 75,654,772 shares of $0.001 par value common stock at September 30, 2010

XENACARE HOLDINGS, INC.

INDEX

Page

PART I – FINANCIAL INFORMATION

PART II – OTHER INFORMATION

PART I – FINANCIAL INFORMATION

ITEM 1.

FINANCIAL STATEMENTS

XenaCare Holdings, Inc. and Subsidiaries

Consolidated Balance Sheets

	September 30,  2010			December 31,  2009
	(Unaudited)
ASSETS
Current Assets
Cash	$	8,483		$	225,019
Accounts receivable		565,227			30,002
Inventory		1,471,674			829,318
Prepaid expenses and other current assets		604,195			172,008
Total Current Assets		2,649,580			1,256,347
Office Furniture and Equipment, net		13,750			—
Other Assets		279,472			273,000
TOTAL ASSETS	$	2,942,802		$	1,529,347
LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)
Current Liabilities
Accounts payable and accrued expenses	$	707,181		$	1,121,889
Notes payable - current		3,327,899			2,177,138
Total Current Liabilities		4,035,080			3,299,028
TOTAL LIABILITIES		4,035,080			3,299,028
COMMITMENTS AND CONTINGENCIES
Shareholder's Equity (Deficit)
Preferred stock, 5,000,000 shares authorized: Series E, $0.001 par value, 267,617 and 79,294 shares issued and outstanding at September 30, 2010 and December 31, 2009		268			79
Common stock, $0.001 par value, 200,000,000 shares authorized: 75,654,772 and 69,742,272 shares issued and outstanding at September 30, 2010 and December 31, 2009, respectively		75,655			69,742
Additional paid-in-capital		9,660,325			7,530,722
Accumulated deficit		(10,828,526	)		(9,370,224	)
Stock Subscription		—			—
Total Shareholders' Equity (Deficit)		(1,092,278	)		(1,769,681	)
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)	$	2,942,802		$	1,529,347

See accompanying unaudited notes to consolidated financial statements

1

XenaCare Holdings, Inc. and Subsidiaries

Consolidated Statements of Operations

(Unaudited)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2010			2009			2010			2009
Revenue:
Product sales	$	735,090		$	8,240		$	2,364,270		$	79,929
Other fee revenue		—			—			—			—
Total revenue		735,090			8,240			2,364,270			79,929
Cost of revenue		230,744			1,947			732,639			24,475
Gross profit		504,346			6,293			1,631,631			55,454
Operating costs and expenses:
Selling and marketing		927,676			127,522			2,410,362			245,460
General and administrative		136,038			252,229			479,035			929,831
Write downs		6,660			7,951			6,660			17,951
Total operating costs and expenses		1,070,374			387,702			2,896,057			1,193,242
Other income (expense)
Interest expense		(99,884	)		(54,572	)		(188,319	)		(130,090	)
Interest income		203			—
Other income		1,192			12,519			1,250			28,093
Other expenses		(1	)		127			(7,010	)		(41,469	)
Total other income (expense)		(98,693	)		(41,926	)		(193,876	)		(143,466	)
Net Loss	$	(664,721	)	$	(423,335	)	$	(1,458,302	)	$	(1,281,254	)
Weighted average shares - basic and diluted		74,698,522			59,491,869			73,220,397			53,938,034
Basic and diluted loss per share	$	(0.01	)	$	(0.01	)	$	(0.02	)	$	(0.02	)

See accompanying unaudited notes to consolidated financial statements

2

XenaCare Holdings, Inc. and Subsidiaries

Consolidated Statements of Cash Flows

(Unaudited)

	Nine Months Ended September 30,
	2010			2009
Cash Flows from Operating Activities:
Net loss	$	(1,458,302	)	$	(1,281,254	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		1,250			951
Allowance for doubtful accounts		34,805			48,697
Stock issued for services		202,400			—
Changes in operating assets and liabilities:
Accounts receivable		(570,031	)		22,512
Inventory		(642,357	)		24,281
Prepaid expenses and other current assets		(432,188	)		163,544
Accounts payable and accrued expenses		122,210			688,741
Cost of rent deposit		(6,472	)		—
Net cash used in operating activities		(2,748,685	)		(332,528	)
Cash Flows from Investing Activities:
Fixed Asset Purchases		(15,000	)		—
Net cash used in investing activities		(15,000	)		—
Cash Flows from Financing Activities:
Proceeds from notes payable		2,554,149			—
Repayments on notes payable		(57,000	)		35,731
Advances from (Payments to) related parties		—			51,850
Stock Subscription		50,000			500,000
Net cash provided by financing activities		2,547,149			587,581
Increase (Decrease) in Cash		(216,536	)		255,053
Cash and cash equivalents, Beginning of Period		225,019			255,053
Cash and cash equivalents, End of Period	$	8,483		$	510,105
Supplemental disclosure of cash flow information:
Cash paid for interest	$	—		$	—
Cash paid for taxes	$	—		$	—
Supplemental disclosure of non-cash investing and financing activities:
Capitalization of debt and other accrued expenses	$	1,883,305		$	—
Conversion of preferred shares	$	—		$	10,715

See accompanying unaudited notes to consolidated financial statements

3

NOTE 1. – ORGANIZATION AND NATURE OF BUSINESS

Organization and Nature of Business

XenaCare Holdings, Inc. (the “Company”, “XenaCare”, “XC Holdings”, “we”, “us” or “our”) was organized under the laws of Florida in June 2005 to formulate, market and distribute a line of clinical and protective nutrition supplement products (“NSPs”) as well as homeopathic medication and detoxification product.

Our Clinical NSP products group includes our proprietary formulations - XenaCor, XenaTri and XenaZyme Plus, which will be sold through mass media buys (radio and television advertising), web sales and other channels of distribution.

On September 29, 2010, XenaCare Holdings entered into a Private Labeling Agreement with Renaissance Health Publishing, LLC of Boca Raton, Florida to market our clinical products. These products address major issues concerning prevention of heart disease. XenaCare will provide the finished products to Renaissance Health who is currently developing the labels, the marketing materials and strategies for these retail products. Because the Renaissance model is to educate the consumer through direct response sales, these unique supplements will necessarily receive greater personal attention by the consumer.

Our Protective NSP product group is directed to the energy/lifestyle performance market. Our initial product, SunPill™, is formulated to protect the skin when exposed to damaging ultraviolet rays. However, during the third quarter of 2010, we had the product reevaluated and as a result were able to extend the shelf life for an additional two years. We are currently in negotiations with a distributor in Cypress to assume the entire line for distribution in the European market. We believe that we will able to recover our product costs and accordingly have not provided for any impairment expense.  

Our Homeopathic Medication product line is lead by Cobroxin. Cobroxin is the first opiate and acetaminophen-free pain reliever available as an over-the-counter formulation clinically proven to treat moderate to severe (Stage 2) pain. Available in a topical gel that relieves pain associated with joints, repetitive stress and arthritis, and in an oral spray that is formulated to relieve lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia, Cobroxin™ is derived from cobra venom.

Our Detoxification product line is led by Zeolite. We exclusively market and distribute Zeolite from Mineral Sciences, LLC within the United States. Zeolite is a cellular cleanse and detoxification product designed as an effective solution for removing heavy metals and toxins from the body. Research has also shown that the product’s ingredients may help reduce viral replication and support healthy blood sugar levels. Additionally, this product improves nutrient absorption, supports immune system function and reduces symptoms of allergies.

Our new Pet Care product line is led by EstraPet™. On September 8, 2010, XenaCare Holdings entered into an exclusive agreement with Dr. Phillip Schoenwetter whereby XenaCare gained all rights to the trademark EstraPet™; to the domain www.estrapet.com and to the United States Patent Pending under the caption "Treatment for Domestic Animals Having Sex Hormone Deficiencies using Soy Germ Isoflavones". EstraPet answers the need for treating the unintended consequences caused by spaying and neutering and is the only known natural hormone modulator available on the market today.

History of the Company

While the Company was organized in 2005, its predecessor, XenaCare LLC was organized in 2001. Thereafter, the Company entered into an exchange agreement with certain members of XenaCare LLC and such members exchanged their interest in XenaCare LLC for an aggregate of 800,000 shares of XenaCare Holdings, Inc. common stock, which represented a value of $1,600,000.

On January 5, 2009, XenaCare amended its Articles of Incorporation to increase the number of authorized shares of common stock from 45 million to 200 million.

4

NOTE 1. – ORGANIZATION AND NATURE OF BUSINESS (Continued)

In May, 2009, NutraPharma, Inc. awarded to XenaCare the US marketing rights to Cobroxin. NutraPharma is a biotechnology company that is developing treatments for adrenomyeloneuropathy, HIV and multiple sclerosis. Cobroxin is the first opiate and acetaminophen-free pain reliever available as an over-the-counter formulation clinically proven to treat moderate to severe (Stage 2) pain. The Company has sales agreements with many major retailers.

In May, 2009, Mineral Sciences, Inc. awarded XenaCare the exclusive license to market and distribute a cellular cleanse and detoxification product called Zeolite for retail distribution designed as an effective solution for removing heavy metals and toxins from the body.

In December, 2009, all of the Company’s subsidiaries were merged into XenaCare Holdings, Inc.

NOTE 2. – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Terms and Definitions

Company

“XenaCare”, “XC Holdings”, “we”, “us” or “our”

ASC

Accounting Standards Codification

ASU

Accounting Standards Update

FASB

Financial Accounting Standards Board

FIFO

First-in, First-out

GAAP (US)

Generally Accepted Accounting Principals

NSP

Nutrition Supplement Product

SEC

Securities Exchange Commission

SFAS or

FAS

Statement of Financial Accounting Standards

Q309-QTR

Three months Ended September 30, 2009

Q309-YTD

Nine months Ended September 30, 2009

Q310-QTR

Three months Ended September 30, 2010

Q310-YTD

Nine months Ended September 30, 2010

Basis of Accounting

The financial statements are prepared using the accrual basis of accounting where revenues and expenses are recognized in the period in which they were incurred. The basis of accounting conforms to accounting principles generally accepted in the United States of America.

Principles of Consolidation and Presentation

In 2010, the financial statements include the accounts of the Company as of December 2009; the Company merged all of its subsidiaries into the Company (XenaCare Holdings, Inc.).

In 2009, the financial statements were consolidated and include the accounts of the Company (XenaCare Holdings, Inc.) and its wholly-owned subsidiaries: BRS, Inc.; XenaCare, LLC; XenaStaff, LLC; and XenaCeutical, LLC and Raw Material Ingredients, Inc. All material intercompany accounts and transactions have been eliminated in consolidation.

Interim Financial Statements

The interim financial statements presented herein have been prepared pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. The interim financial statements should be read in conjunction with the Company’s annual financial statements of 2009, notes and accounting policies included in the Company’s 2009 Annual Report. In the opinion of management, all adjustments which are necessary to provide a fair presentation of financial position as of September 30, 2010and the related operating results and cash flows for the interim period presented have been made. All adjustments are of a normal recurring nature. The results of operations, for the period presented are not necessarily indicative of the results to be expected for the year ended December 31, 2010.

5

NOTE 2. – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Use of Estimates

The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Although these estimates are based on management’s knowledge of current events and actions it may undertake in the future, they may ultimately differ from actual results.

Risks and Uncertainties

The Company’s business could be impacted by continuing price pressure on its product manufacturing, acceptance of its products in the marketplace, new competitors, changes in federal and/or state legislation and other factors. Adverse changes in these areas could negatively impact the Company’s financial position, results of operations and cash flows.

Going Concern

As shown in the accompanying financial statements, the Company’s operating and capital requirements in connection with operations have been and will continue to be significant. The recurring losses from operations and increased contractual agreements raise doubt about the Company’s ability to continue as a going concern. Based on current plans, the Company anticipates that revenues earned from Cobroxin and Zeolite product sales will be the primary source of funds for operating activities. In addition to existing cash, the Company may rely on bank borrowing, if available, or sales of securities to meet the basic capital and liquidity needs for the next 12 months. Additional capital may be sought to fund the expansion of product lines and marketing efforts, which may also include bank borrowing, or a private placement of securities. Our ability to continue as a going concern is dependent upon our ability to generate sales from our new products and our obtaining adequate capital to fund losses until we become profitable. There can be no assurance that management’s plans will be successful.

The financial statements have been prepared on a “going concern” basis and accordingly do not include any adjustments that might result from the outcome of this uncertainty.

Accounts Receivable

Accounts receivable are reported at net realizable value. The Company establishes an allowance for doubtful accounts based upon factors pertaining to the credit risk of specific customers, historical trends, and other information. Delinquent accounts are written-off when it is determined that the amounts are uncollectible. At September 30, 2010 and December 31, 2009, the allowance for doubtful accounts was $83,502 and $48,697, respectively.

Inventory

Inventory is reported at the lower end of cost or market on the first-in, first-out (FIFO) method. Our inventory is subject to expiration and accordingly quantities purchased and sell through rates are periodically monitored for potential overstocking or pending expiration as a basis for establishing the appropriate reserve for any estimated expiration or obsolescence. The Company’s principal brands are XenaCor, XenaTri, XenaZyme and its newest product lines, Cobroxin, Zeolite, and EstraPet™.

At both September 30, 2010 and December 31, 2009, the allowance for obsolete or expired inventory was $55,544.

Office Furniture and Equipment

Office furniture and equipment are recorded at cost and depreciation is provided using the straight-line method over the estimated useful lives of the assets. Expenditures for repairs and maintenance of equipment are charged to expense as incurred. Major replacements and betterments are capitalized and depreciated over the remaining useful lives of the assets.

Office furniture and equipment is depreciated over various lives ranging from 3 to 7 years. Depreciation expense for the nine months ended September 30, 2010 and the year ended December 31, 2009 was $1,250 and $1,482, respectively.

6

NOTE 2. – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Revenue Recognition

The Company’s product revenues represent primarily sales of SunPill®, XenaCor, XenaTri, XenaZyme and Cobroxin. Revenue is recognized when a product is shipped. The Company outsources its fulfillment (delivery) process to a third party for most of its products.

The Company’s revenue recognition policies are in compliance with ASC Topic 605, Revenue Recognition, which establishes criteria that must be satisfied before revenue is realized or realizable and earned. The Company recognizes revenue when all of the following four criteria are met:

·

persuasive evidence of a sales arrangement exists,

·

delivery has occurred,

·

the sales price is fixed or determinable, and

·

collectability is probable.

Shipping and handling charges related to sales transactions are recorded as sales revenues when billed to customers or included in the sales price in accordance with ASC Topic 605, shipping and handling costs are included in cost of revenue.

The Company accepts product returns and will issue a credit, refund or product exchange. To date, product returns have occurred but are not considered material. The Company does not have a product return reserve established.

Research and Development

The Company does not engage in research and development as defined in ASC Topic 730 Research and Development Costs. However, the Company does incur formulation costs that include salaries, materials and consultant fees. These costs are classified as selling, general and administrative expenses in the consolidated statements of operations.

Income Taxes

We recognize deferred tax assets and liabilities based on differences between the financial reporting and tax bases of assets and liabilities using the enacted tax rates and laws that are expected to be recovered. We provide a valuation allowance for deferred tax assets for which we do not consider realization of such assets to be more likely than not.

Earnings per share

The Company computes basic and diluted earnings per share amounts in accordance with ASC Topic 260, Earnings per Share. Basic earnings per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.

Segment Information

ASC Topic 280, Disclosures about Segments of an Enterprise and Related Information, established standards for the way that public business enterprises report information about operating segments in annual financial statements and requires those enterprises to report selected information about operating segments in interim financial reports issued to stockholders. The Company operates in one segment for management reporting purposes.

7

NOTE 3. – RECENT ACCOUNTING PRONOUNCEMENTS

Recent accounting pronouncements that the Company has adopted or that will be required to adopt in the future are summarized below.

Allowance for Credit Losses: In July 2010, the FASB issued ASU No. 2010-20 “Receivables” (Topic 310). ASU No. 2010-20 provides financial statement users with greater transparency about an entity’s allowance for credit losses and the credit quality of its financing receivables. This update is intended to provide additional information to assist financial statement users in assessing an entity’s credit risk exposures and evaluating the adequacy of its allowance for credit losses. The amendments in this update apply to both public and nonpublic entities with financing receivables, excluding short-term trade accounts receivable or receivables measured at fair value or lower of cost or fair value. The objective of the amendments in ASU No. 2010-20 is for an entity to provide disclosures that facilitate financial statement users’ evaluation of (1) the nature of credit risk inherent in the entity’s portfolio of financing receivables, (2) How that risk is analyzed and assessed in arriving at the allowance for credit losses and (3) The changes and reasons for those changes in the allowance for credit losses. The entity must provide disclosures about its financing receivables on a disaggregated basis. For public entities ASU No. 2010-20 is effective for interim and annual reporting periods ending on or after December 15, 2010. For nonpublic entities ASU No. 2010-20 will become effective for annual reporting periods ending on or after December 15, 2011. The Company is evaluating the impact ASU No. 2010-20 will have on the financial statements.

Technical Amendments: In August 2010, the FASB issued ASU No. 2010-21 “Accounting for Technical Amendments to Various SEC Rules and Schedules” and ASU No. 2010-22 “Accounting for Various Topics – Technical Corrections to SEC Paragraphs”. ASU No 2010-21 amends various SEC paragraphs pursuant to the issuance of Release no. 33-9026: Technical Amendments to Rules, Forms, Schedules and Codification of Financial Reporting Policies. ASU No. 2010-22 amends various SEC paragraphs based on external comments received and the issuance of SAB 112, which amends or rescinds portions of certain SAB topics. Both ASU No. 2010-21 and ASU No. 2010-22 are effective upon issuance. The amendments in ASU No. 2010-21 and No. 2010-22 will not have a material impact on the Company’s financial statements.

Other ASUs not effective until after September 30, 2010, are not expected to have a significant effect on the Company’s consolidated financial position or results of operations

8

NOTE 4. – INVENTORY

Significant components of inventory at September 30, 2010 and December 31, 2009 consist of the following:

	2010			2009
Bulk product	$	137,365		$	96,000
Merchandise inventory		1,371,246			788,862
		1,508,611			884,862
Allowances for expiration		(36,937	)		(55,544	)
	$	1,471,674		$	829,318

Bulk product – Bulk product consists of completed unpackaged loose SunPill® product that has been stored in barrels awaiting commercial packaging to make it market ready for distribution. As discussed below, the Company has arranged for the disposition of its existing SunPill® inventory and since it no longer considers the SunPill® inventory market ready for distribution, package SunPill® has been reclassified as bulk product. Subsequent to December 31, 2009 the Company has arranged for the liquidation of this merchandize along with any bulk product. The Company has fully reserved for estimated loss associated with the disposition of SunPill® inventory. The SunPill® inventory has been retested and the shelf life has been extended for two years.

Merchandise inventory - Merchandise inventory consists primarily of the Cobroxin product along with lesser quantities of XenaCore. Our formulations are batch controlled and carry an expiration date in accordance with applicable government regulations. Any product approaching their expiration date have been destroyed and removed from the inventory. Continued delays in fully implementing our marketing and distribution programs have resulted in significantly slower than anticipated sales in 2009 and 2008. Consequently, establishes an allowance on the remaining inventory, based on the estimated sell through rate for each product, before their expiration.

NOTE 5. – ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Significant components of accounts payable and accrued expenses at September 30, 2010 and December 31, 2009 consist of:

	2010		2009
Trade payables	$	458,088	$	447,785
Accrued accounting and legal fees		21,500		28,500
Accrued payroll		—		433,333
Accrued interest		203,281		158,104
Other accrued expenses		24,312		54,167
	$	707,181	$	1,121,889

9

NOTE 6. – NOTES PAYABLE - CURRENT

Significant components of notes payable – current at September 30, 2010 and December 31, 2009 consist of:

	2010		2009
Related parties	$	196,750	$	500,138
Shareholder loans		1,980,288		700,000
Sun Packing, Inc.		977,000		977,000
Advances on factored receivables		173,861		—
	$	3,327,899	$	2,177,138

Related Parties - Notes payable to related parties were issued in various traunches, each mature one year from issuance and bear interest at 15%. The lenders are related parties to the Company through common executive management as our CFO and President are also officers in the lenders. The notes matured on June 30, 2009 however, during the first quarter of 2010, the parties agreed to convert $346,387 of these notes into 34,639 shares of Series E preferred stock. In addition, during the third quarter of 2010, the Company borrowed approximately $58,000 which provided supplemental working capital.

Shareholder Loans – Unsecured notes payable to a shareholder were issued in various traunches commencing in January 2009, each mature one year from issuance and bear interest at from 12%-15%. During the first quarter of 2010, the shareholder advanced an additional $1,500,000 and then converted $1,000,000 of outstanding debt into 100,000 shares of Series E preferred shares. During the third quarter of 2010, the shareholder advanced an additional $50,000, the proceeds of which were used to acquire product and promote its brand.

During the third quarter of 2010, the Company borrowed $130,288 from another shareholder, the proceeds of which were used to acquire inventory. Interest accrues at 15% and the note matures in August 2011.

Sun Packing, Inc. - The Sun Packing, Inc. note originated during merger negotiations with the Company during the third and fourth quarters of 2008. The parties were unable to reach an agreement on several key issues and the merger negotiations were discontinued. The note is personally guaranteed by our officers and bears interest at 6%. The note is payable upon demand. To date the note has not been called.

Advances on Factored Receivables - The Company has entered into a factoring arrangement whereby the factor advances 85% of invoices placed for factoring. Placing invoices for factoring is at the discretion of the Company. Invoices are factored with recourse and advances accrue interest at approximately 16.2%.

10

NOTE 7. – COMMITMENTS AND CONTINGENCIES

The Company, during the year operated under several material agreements as listed below:

Consulting service / employment agreements

·

Employment agreements - Employment agreements with two individuals for their services in the areas of sales (our President), operations and mergers and acquisitions (our CFO) were terminated on December 31, 2009 by mutual consent. All accrued and unpaid compensation and benefits totaling $562,500 were converted into 56,250 Series E preferred shares. New verbal employment agreements were entered into with these individuals, which provide for monthly draws of $5,000 and quarterly bonus based on performance. The agreements can be terminated at any time.

·

Beauty Development - In December 2009, we entered into a three year agreement with Beauty Development Corporation, to provide distribution management, development and product merchandising services. The Company issued 8,475 shares of Series E preferred shares which calls for performance based vesting over the three year term. This agreement has been fully prepaid.

·

Dynamic Equities – During the third quarter of 2010, the Company entered into a new consulting agreement with Dynamic Equities Securities, Inc. mergers and acquisitions, and working capital. The terms of the agreements provide for 36 months. The contract was prepaid through the issuance of 1 million common shares valued at $0.12 each, the fair value of the shares at the execution of the agreement. Accordingly, $120,000 has been recorded as a prepaid expense and will be amortized over the next 36 months.

Marketing agreements

·

Creative Management and Arnot – During the third quarter of 2010, the Company entered into a new image marketing and branding agreement with Creative Management, Inc. and a companion spokesperson agreement with Dr. Bob Arnot, a nationally known medical and news correspondent. The terms of the agreements provide for image marketing and branding services for 36 months. The contract was prepaid through the issuance of 500,000 common shares valued at $.12 each, the fair value of the shares at the execution of the agreement. Accordingly, $60,000 has been recorded as a prepaid expense and will be amortized over the next 36 months.

·

Nutritional Alliances, Inc - In December 2009, we also entered into a three year agreement with Nutritional Alliances, Inc to provide market penetration and expand our customer base. The Company issued 8,475 shares of Series E preferred shares which calls for performance based vesting over the three year term. This agreement has been fully prepaid.

Lease for office facilities

·

Boca Raton office – In March 2010, the Company entered into a 3 year lease agreement for its new corporate headquarters in Boca Raton, Florida. The Company occupied the new facility in June 2010. The lease provides for the first fourth months of rent waived.

Summary of commitments

	2010		2011		2012		2013		Beyond		Total
Boca Raton office lease (current)	$	8,296	$	35,189	$	38,513	$	16,610		—	$	98,608

11

NOTE 8. – COMMON AND PREFERRED STOCK

Common Stock

The Company’s shares commenced quotation on the Over the Counter Bulletin Board on March 5, 2008. The Company’s quotation symbol is XCHO:OTC.

During the first quarter of 2009, the Company issued 10,748,340 shares to convert 500,000 Preferred A shares.

Also during the first quarter of 2009, the Company had a net retirement of 33,333 shares in several exchange transactions, in which 100,000 shares were retired in exchange for 66,667 shares issued.

During the second quarter of 2009, the Company retired 500,000 non vested shares which were returned to the Company.

In September 2009, we sold 12,500,000 shares of common stock to an accredited investor for $500,000.

During the fourth quarter of 2009, we issued 3,000,750 and 1,000,000 shares of common stock in exchange for services from various consultants. As part of that issuance included shares to retire 2,632 Preferred F shares issued originally issued in exchange for professional services in connection with the Sun Packing transaction.

During the third quarter of 2010, we issued 1,600,000 shares of common stock in exchange for services from various consultants. The shares were recorded at their fair value. Appropriate expenses or prepaid services for long term agreements have been recorded.

Preferred Stock

During the first quarter of 2009, the Company converted 500,000 shares of Preferred A to 10,748,340 shares of restricted common stock.

During December of 2009 the board of directors authorized the issue of up to 300,000 shares of Series “E” preferred stock. The stated value of each share is ten $10.00 per share. Each shares to be issued bears a dividend rate of fifteen (15%) percent and has voting rights as if converted to common shares of the corporation. The conversion of such shares is the stated value divided by the common stock price, as published by NASDAQ, at the time of issue. For each shares of common stock issued by this series is entitled to one warrant share as determined by the board of directors. These warrants are cashless, fully paid, and non-assessable.

During the fourth quarter of 2009, the company issued 79,294 shares of preferred stock series “E.” 68,000 shares were issued to corporate executives for accrued salaries and stockholder loans and 10,000 shares were issued as a bonus to one employee and one outside consultant.

During the first quarter of 2010, all accrued and unpaid compensation and benefits for two consultants, one who provided acquisition and financing services and one who provided administration services, totaling $536,918 were converted into 53,686 Series E preferred shares. There services were terminated in 2009 and no new agreements were entered into with these individuals.

During the first quarter of 2010, $1,000,000 of outstanding debt was converted into 100,000 shares of Series E preferred shares.

During the first quarter of 2010, two employees (the CFO and the President) who are lenders to the Company converted $346,487 of their outstanding debt into 34,639 shares of Series E preferred stock.

12

NOTE 9. – SUPPLIER CONCENTRATION

Our Cobroxin™ and Zeolite™ products, are sold under an exclusive long-term marketing and distribution agreement from the manufacturer, however we do not possess rights to the formulation. Should the manufacture fail, for any reason to produce the product in the quantities we require, our business may be adversely affected.

NOTE 10. – CUSTOMER CONCENTRATION

Our Cobroxin™ products comprise essentially all of sales in 2010 and are sold both to retail customers directly and to retailers, grocery and pharmacies. Our products are sold to two significant retailers, who account for 48.6% and 32.9% respectively of our sales during the nine months ended September 30, 2010. Our sales are made under cancellable agreements. A loss of either of these key customers, until we complete our full commercial launch, for any reason, could adversely affect our business.

13

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS

Introduction

Management’s discussion and analysis of financial condition and results of operations is provided as a supplement to our condensed financial statements and accompanying notes to help provide an understanding of our financial condition, changes in financial condition and results of operations. It provides a general description of our business, trends in our industry, as well as significant transactions that have occurred that we believe are important in understanding our financial condition and results of operations. Management’s discussion and analysis of financial condition and results of operations is organized as:

·

Caution concerning forward-looking statements. This section discusses how certain forward-looking statements made by us throughout this discussion and analysis are based on management’s present expectations about future events and are inherently susceptible to uncertainty and changes in circumstance.

·

Overview and Operations. This section discusses our product offering, the business environment and the regulatory environment we operate in

·

Recent accounting pronouncements. This section provides an analysis of relevant recent accounting pronouncements issued by the FASB and the effect of those pronouncements.

·

Critical accounting policies and estimates. This section discusses those accounting policies that are both considered important to our financial condition and results of operations, and require significant judgment and estimates on the part of management in their application for the nine months ended September 30, 2010.

·

Results of operations. This section provides an analysis of our results of operations for three and nine months ended September 30, 2010 relative to the comparative prior year period presented in the accompanying statements of operations.

·

Liquidity and capital resources. This section provides an analysis of our cash flows, capital resources and off-balance sheet arrangements and our contractual obligations as of September 30, 2010.

Caution Concerning Forward-Looking Statements

The SEC encourages companies to disclose forward-looking information so that investors can better understand a company’s future prospects and make informed investment decisions. This document contains such “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, particularly statements anticipating future growth in revenues, operating income and cash flow. Statements that are predictive in nature, that depend upon or refer to future events or conditions or that include words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “will,” “estimates,” and similar expressions are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results and performance to be materially different from any future results or performance expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, history of operating losses and accumulated deficit; possible need for additional financing; competition; dependence on management; risks related to proprietary rights; government regulation; and other factors discussed in this report and our other filings with the SEC.

Overview and Operations

XenaCare Holdings, Inc. (the “Company”, “XenaCare”, “we”, or “us”) was organized in 2005 to market and distribute proprietary formulations of clinical and protective nutrition supplement products (“NSPs”) as well as homeopathic medication and detoxification products. In the three and six months ended September 30, 2010 substantially all of our revenues were from Cobroxin, the first opiate and acetaminophen- free pain reliever available as an over-the-counter formulation clinically proven to treat moderate to severe (Stage 2) pain.

14

We formulate some of our products and obtain others, including Cobroxin, through exclusive marketing agreements. We do not manufacture our products directly but obtain finished product from contract manufacturers. We also source all warehousing and distribution services for our products from third party contractors. We market to a variety of distribution channels, including:

·

mass market retailers, such as Meijers

·

supermarkets, such as Kroger, Publix and Winn-Dixie

·

drugstore chains, such as Walgreen, CVS and RiteAid

·

independent pharmacies such as CDMA and NACDS

·

health and natural food stores through Tree of Life

·

healthcare practitioners, and

·

direct to consumer by e-commerce, including amazon.com, overstock.com and cobroxin.com.

Our concentrated advertising program was increased in the 2nd quarter to support our major retailers. XenaCare is making a strong footprint in all areas of the distribution grid as Cobroxin has been well received for retail placement. Some of our retailers include CVS, Walgreens, RiteAid, Meijer, Publix, Winn Dixie, Hannaford, Duane Reade, Stop and Shop, and many others. Our media plan was to engage in print advertising first followed by T.V. and radio. From our feedback, the retailers are very enthused about our advertising roll-out in support of the product. Indications are, this has been a very successful campaign.

Now, with the addition of the Television and Radio campaign, we should generate a return on investment far surpassing the advertising dollars spent. This additional advertising campaign will complete the full branding and advertising support of the products at the retail level creating a strong 2^nd half of fiscal year 2010. We have already seen an increase of repeat orders from several of our retail chains.

The Company currently operates or is in the process of developing the following product lines:

·

Our line of Clinical NSPs includes XenaCor, XenaZyme Plus and XenaTri. These products are poly-formulas designed to address key multi-factors in disease processes such as atherosclerosis and diabetes.

·

Our line of Protective NSPs currently consists of SunPill^®, which is a revolutionary nutritional supplement that is designed to defend your skin when exposed to damaging ultraviolet rays and sun damage.

·

Our line of Homeopathic Medication currently consists of Cobroxin which is the first opiate and acetaminophen-free pain reliever available as an over-the-counter formulation clinically proven to treat moderate to severe (Stage 2) pain.

·

Our line of Detoxification products currently consists of Zeolite which is a cellular cleanse and detoxification product designed as an effective solution for removing heavy metals and toxins from the body.

·

Our line of Pet Care products is led by EstraPet™. EstraPet answers the need for treating the unintended consequences caused by spaying and neutering and is the only known natural hormone modulator available on the market today.

Up until the third quarter of 2009, substantially all revenues to date have been generated from sales of historical Clinical NSPs, XenaCor, XenaTri and XenaZymePlus and Protective NSPs, SunPill ^® . Commencing in the third quarter of 2009 we began to establish our Homeopathic product lines. These newer product lines now generate the bulk of our revenue. Since our inception, we were profitable in one quarter, Q110-QTR.

We purchase all of our products and supplies from third-party sources. Our contract with NutraPharma provides for a minimum quarterly purchase of Cobroxin as previously reported. Our purchases are made on an order-by-order basis. In the event that a current manufacturer is unable to meet our manufacturing and delivery requirements at some time in the future, we may suffer short-term interruptions of delivery of certain products while we establish an alternative source.

15

Clinical NSPs

Our line of Clinical NSPs seek to shift a portion of current consumer “out-of-pocket” spending on ineffective and/or incomplete self-care and healing products, obtained through a myriad of retail and internet distribution systems. Our Clinical NSPs provide consumers with access to proprietary nutritional supplements.

XenaCor, XenaTri and XenaZymePlus are specifically formulated to support and help maintain patient healthcare for many risk factors, including those related to homocysteine levels, lipid control, blood flow and blood pressure. These NSPs are formulated under the guidelines of the Food and Drug Administration (“FDA”) and its regulation of the Nutritional Supplement and Health Education Act. However, while the FDA regulates the nutritional supplement industry, no approvals by the FDA are required for our products.

·

We believe our Clinical NSPs listed below support and maintain the following:

·

XenaCor: the lowering of serum cholesterol, C-reactive protein and homocysteine levels. This product was designed to support cardiovascular health.

·

XenaTri: the lowering of triglycerides and raising of HDL. This product was designed to support cardiovascular health.

·

XenaZyme Plus: increases the body’s oxygen-carrying capacities. This product was designed to support digestion.

We believe these NSPs significantly differentiate themselves from our competition including self-help vitamin and herbal product manufacturers and distributors. These NSPs are formulated to support the delivery of measurable subjective (improved medical history) and/or objective (laboratory results) effects regardless of what other medications or supplements the patient is taking. We believe that these NSPs support significant positive health actions and outcomes without deleterious adverse side effects. The Company does not diagnose nor treat diseases. Our products are only formulated to support and maintain an individual’s health and well being.

On September 29, 2010, XenaCare Holdings entered into a Private Labeling Agreement with Renaissance Health Publishing, LLC of Boca Raton, Florida to market our clinical products.  These products address major issues concerning prevention of heart disease. XenaCare will provide the finished products to Renaissance Health who is currently developing the labels, the marketing materials and strategies for these retail products. Because the Renaissance model is to educate the consumer through direct response sales, these unique supplements will necessarily receive greater personal attention by the consumer.

Protective NSPs

SunPill^®, a nutritional supplement that is designed to defend your skin from photo-aging and sun damage, was developed by the founder of Banana Boat, and Sea and Ski, an inventor at the forefront of protecting skin from the damaging effects of the sun. We have acquired the worldwide rights to produce and distribute the SunPill ^® . We believe the composition of the SunPill ^® , when taken daily, protects the skin against the effects of ultraviolet (UV) radiation from the sun or other sources which include sunburn, skin redness, swelling, immune suppression, photo-damage.

Homeopathic Medication

XenaCare exclusively markets and distributes Cobroxin for Nutrapharma Corporation (OTCBB: NPHC) within the United States. On November 3, 2009, XenaCare announced that the Chain Drug Marketing Association (CDMA) will begin inventorying Cobroxin for redistribution to its member pharmacies. The CDMA currently has over 6,000 independent pharmacy members throughout the United States.

Cobroxin is the first opiate and acetaminophen-free pain reliever available as an over-the-counter formulation clinically proven to treat moderate to severe (Stage 2) pain. Available in a topical gel that relieves pain associated with joints, repetitive stress and arthritis, and in an oral spray that is formulated to relieve lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia, Cobroxin is derived from cobra venom . The medical application of cobra venom was incorporated into the Homeopathic Pharmacopoeia Materia Medica in the 1800s along with several other snake venoms. In the early 1900s, Calmette (of BCG fame) investigated the use of cobra venom in the treatment of cancer in mice. It was subsequently applied clinically to subjects with cancer where it established a reputation in France for relieving pain. In 1936, Macht, a researcher within the pharmaceutical company, Westcott, Hynson and Dunning, showed that cobra venom, when injected in minute doses, produced analgesic effects that were superior to morphine in activity. In fact, cobra venom was employed when morphine was no longer effective or when patients became addicted to the opiate. Cobra venom proved to be 80% effective in the clinic for the treatment of headache and arthritis pain and it

16

allowed long-term control of chronic pain conditions without addictive problems. A feature of this venom product was its slow onset of analgesic activity however its activity is prolonged. In 1938, acceptance of homeopathic medicine including cobra venom was incorporated into the Food, Drug & Cosmetic Act sponsored by Royal Copeland. In the latter part of the last century cobra venoms were studied for the treatment of severe pain but also rheumatism, trigeminal neuralgia, asthma, ocular therapy, and neuroses.

Today, Cobra venom is being studied for treating various forms of pain, cancers, autoimmune and neurological disorders. Researchers have proven that cobra venom contains constituents that control pain and inflammation. Researchers in China are examining the possibility that cobra venom can be used to treat drug addiction. The National Cancer Institute in Italy has participated in Chinese clinical trials to assess the efficacy of Cobra toxins in controlling post operative pain and moderate to severe cancer pain. More recently Cobra toxin has been reported to kill mesothelioma and lung cancer cells, 75 years after the first reports in the 1933 issue of the medical journal Lancet.

XenaCare is supporting its fast-growing network of retailers carrying Cobroxin with a comprehensive multi-million dollar national advertising campaign that includes direct response, print media, television commercials and national sponsorship programs. We market and distribute our products through a variety of retail outlets, including chain drug stores, independent pharmacies, grocery chains, mass marketers, catalog companies and e-commerce sites. Cobroxin was marketed through Internet sales during the last quarter of 2009, and in the first quarter of 2010 the product has been accepted by 40% of the 105,000 retail stores (as reported in the trade publication, Chain Drug Review) selling healthcare products across the country.

XenaCare has purchased advertising in a comprehensive array of men’s, women’s and specialty magazines. The ads made their debut in November 2009 and are projected to generate about 108 million reader impressions over a 3-month period. Cobroxin will also be featured through the distribution of 18 million retail catalogs throughout the US.

Additionally, the Company has been authorized to use the American Arthritis Foundation’s logo on packaging, Websites, Customer websites and to send out direct mailings to 100,000 Arthritis foundation members. XenaCare Holdings is advertised in the 2010 Super Bowl XLIV Game Program, the NFL Alumni Guide program and Yearbook, and will advertise in the 2010 NBA Allstar as well as in the official annual publication of NASCAR that will be seen by 8,000,000 attendees. XenaCare is also advertising in Prevention, Arthritis Today, Shape, Allure, Woman’s Day, Men’s Journal, Martha Stewart Living, Balancing Act, Lifetime and Redbook. Television commercials where we market-tested in June 2010. XenaCare has also contracted to publish Cobroxin advertisements in 2010 Major League Baseball (MLB) yearbooks. The advertisements are scheduled to run in the yearbooks of 6 major league cities, including the New York Mets, the Los Angeles Dodgers and the Chicago Cubs. In addition to its marketing campaigns, XenaCare is participating in an athletic sponsorship with Megan Wallin, a professional beach volleyball player on the AVP Tour. Megan, a Florida native, has proven to be a strong force on the sand and in the world of business and has had six professional wins and 10 finals appearances in 2009; she also competed against the two-time gold medalists from the 2004 Athens Olympics and 2008 Beijing Olympics. Her goal 2010 is to make the U.S. Olympic, Megan is rated #1 in Florida and in the top 30 in the world.

Cobroxin is available to independent pharmacy owners through membership in the Chain Drug Marketing Association (CDMA), one of the largest pharmacy organizations representing more than 6,000 outlets in 32 states. Additionally, Cobroxin will be sold through most major drugstore chains, mass marketers, Cardinal Wholesale, a $100/B health care distributor, and food giants, as well as online at: Cobroxin.com, Amazon.com, Overstock.com and Drugstore.com. More than 200 brokers also Market Cobroxin through retail outlets.

17

During the first quarter of 2010, the Company entered into agreements for the sale of Cobroxin through major retail outlets. They are:

AMAZON.COM	AMERIMARK
BENCHMARK	CDMA
CVS	DERMADOCTOR
DR. LEONARD’S	DRUG EMPORIUM
DRUGSTORE.COM	DUANE READE
EVITAMINS	HANNAFORD
HARDTOFIND BRANDS	HD SMITH
HEALTHY PETS	IMPERIAL DISTRIBUTORS
JOHNSON SMITH	KERR DRUG
KINNEY DRUG	MAX-WELNESS
MEIJER	NATURAL HEALTH CENTER
MUTUAL DRUG CO.	OVERSTOCK.COM
UNIVERSAL DIRECT (SUPPORT PLUS)	QUICK2YOU
VALUE DRUG	VITAMIN/PURITAN PRIDE
WALGREENS	WINN DIXIE
RiteAid	Publix
GNC	NACDS
Cardinal Wholesale

Animal Care

EstraPet™ is a treatment for domestic animals having sex hormone deficiencies utilizing patent pending process of Soy Germ Isoflavones. EstraPet™ answers the need for treating the unintended consequences caused by spaying and neutering and is the only known natural hormone modulator available on the market today.

None of our customers are required to order any minimum quantities of Cobroxin.

Detoxification

Zeolite is a cellular cleanse and detoxification product designed as an effective solution for removing heavy metals and toxins from the body. Zeolite is an effective solution for removing heavy metals and toxins from the body. Research has also shown that the product's ingredients may help reduce viral replication and support healthy blood sugar levels. Additionally, this product improves nutrient absorption, supports immune system function and reduces symptoms of allergies.

Formulation of NSPs

The Company has no patent protection for any of its products or services, except the SunPill^® but has multiple trademark protection on certain service marks currently in commerce. We have historically expensed our formulation costs and do not have any separately itemized research and development expenses.

Manufacturing and Supplies

The Company uses contracted third parties to manufacture its products and to provide raw materials. The third party manufacturers are generally responsible for receipt and storage of raw material, production, packaging and labeling of finished goods. At present, the Company is dependent upon manufacturers for the production of all of its products and, should the manufacturers discontinue their relationship with us, the Company’s sales could be adversely impacted. The Company believes at the present time it will be able to obtain the quantity of products and supplies needed to meet orders.

In the event that a current manufacturer is unable to meet our manufacturing and delivery requirements for our clinical and protective NSPs at some time in the future, we may suffer short-term interruptions of delivery of certain products while we establish an alternative source. While we believe alternative sources are in these cases readily available and we have also established working relationships with several third-party suppliers and manufacturers, none of these agreements are long term.

Our Cobroxin and Zeolite products, are sold under an exclusive long-term marketing and distribution agreements from the manufacturers, however we do not possess rights to the formulation. Should a manufacture fail, for any reason to produce the product in the quantities we require, our business may be adversely affected.

18

We also rely on third-party carriers for product shipments, including shipments to and from our distribution facilities. We are, therefore, subject to the risks, including employee strikes and inclement weather, associated with our carrier’s ability to provide delivery services to meet our fulfillment and shipping needs. Failure to deliver products to our customers in a timely and accurate manner would harm our reputation, our business and results of operations.

Governmental Regulation

The Federal Drug Administration (FDA) oversees product safety, manufacturing, and product information, such as statements on the product’s label, package inserts, and accompanying literature. The FDA has promulgated regulations governing the labeling and marketing of dietary and nutritional supplement products. The regulations include:

·

the identification of dietary or nutritional supplements and their nutrition and ingredient labeling;

·

requirements related to the wording used for statements about nutrients, health statements, and statements of nutritional support;

·

labeling requirements for dietary or nutritional supplements for which “high potency, ”antioxidant,” and “transfatty acids” statements are made;

·

notification procedures for statements on dietary and nutritional supplements; and

·

pre-market notification procedures for new dietary ingredients in nutritional supplements.

We utilize a substantiation program that involves the compilation and review of scientific literature pertinent to the ingredients contained in each of our products. We continuously update our substantiation program to expand evidence for each of our product statements and notify the FDA of certain types of performance statements made in connection with our products.

In certain markets, including the United States, specific statements made by us with respect to our products may change the regulatory status of a product. For example, a product sold as a nutritional supplement but marketed as a treatment, prevention, or cure for a specific disease or condition would likely be considered by the FDA or other regulatory bodies as an unapproved drug and asked to be removed from the market. To maintain the product’s status as a nutritional supplement, the labeling and marketing must comply with the provisions in the Dietary Supplement Health and Education Act of 1994 (DSHEA) and the FDA’s extensive regulations. As a result, we have procedures in place to promote and enforce compliance by our employees related to the requirements of DSHEA, the Food, Drug and Cosmetic Act, and various other regulations. Because of the diverse scope of regulations applicable to our products, and the varied regulators enforcing these regulatory requirements, determining how to conform to all requirements is often open to interpretation and debate. As a result, we can make no assurances that regulators will not question any of our actions in the future, even though we have put continuing effort into complying with all applicable regulations.

Nutritional supplements are also subject to the Nutrition, Labeling and Education Act and various other acts that regulate health statements, ingredient labeling, and nutrient content statements that characterize the level of nutrients in a product. These acts prohibit the use of any specific health statement for nutritional supplements unless the health statement is supported by significant scientific research and is pre-approved by the FDA.

Regulators such as the Federal Trade Commission (FTC) regulate marketing practices and advertising of a company and its products. In the past several years, regulators have instituted various enforcement actions against numerous nutritional supplement companies for false and/or misleading marketing practices, as well as misleading advertising of certain products. These enforcement actions have resulted in consent decrees and significant monetary judgments against the companies and/or individuals involved. Regulators require a company to convey product statements clearly and accurately, and further require marketers to maintain adequate substantiation for their statements. The FTC requires such substantiation to be competent and reliable scientific evidence. Specifically, the FTC requires a company to have a reasonable basis for the expressed and implied product statement before it disseminates an advertisement. A reasonable basis is determined based on the statements made, how the statements are presented in the context of the entire advertisement, and how the statements are qualified. The FTC’s standard for evaluating substantiation is designed to ensure that consumers are protected from false and/or misleading statements by requiring scientific substantiation of product statements at the time such statements are first made. The failure to have this substantiation violates the Federal Trade Commission Act.

19

Critical Accounting Policies and Estimates

The preparation of financial statements and related disclosures in conformity with U.S. generally accepted accounting principles and the Company’s discussion and analysis of its financial condition and operating results require the Company’s management to make judgments, assumptions, and estimates that affect the amounts reported in its Financial Statements and the accompanying notes. Note 2, “Summary of Significant Accounting Policies” of this Form 10-Q and the Notes to Consolidated Financial Statements in the Company’s 2009 Form 10-K describes the significant accounting policies and methods used in the preparation of the Company’s Consolidated Financial Statements. Management bases its estimates on historical experience and on various other assumptions it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates and such differences may be material.

Management believes the Company’s critical accounting policies and estimates are those related to revenue recognition, accounts receivable and allowance for doubtful accounts, inventory valuation and income taxes. Management considers these critical policies because they are both important to the portrayal of the Company’s financial condition and operating results and they require management to make judgments and estimates about inherently uncertain matters.

Recent Accounting Pronouncements

Recent accounting pronouncements that the Company has adopted or that will be required to adopt in the future are discussed in Note 2 “Summary of Significant Accounting Policies” in the notes to the interim financial statements included in this filing.

Results of Operations

Comparison of the three months ended September 30, 2010 (“Q210-QTR”) to the three months ended September 30, 2009 (“Q209-QTR”)

Net Revenues - Total net revenues increased $726,850 or 8,821%, to $735,090 (Q310-QTR) from $8,240 (Q309-QTR). We began redirected our efforts and allocated available resources to concentrate on the marketing, promotion and distribution of Cobroxin in the third quarter of 2009. That initial effort was directed primarily to internet based marketing directly to consumers. During the fourth quarter of 2009 and on into the current quarter, we began phase two of our marketing strategy which expanded our focus to retailers in the food and drug industry. In the first quarter of 2010 we have added a significant number of retailers, cataloguers and drug chains as customers, as discussed above. Sales in Q309-QTR were primarily the result of our Clinical and Protective NSPs whereas sales in Q310-QTR were primarily from Homeopathic Medication products, specifically Cobroxin.

Cost of Revenues - Total cost of revenues increased $228,797 or 8,821%, to $230,744 (Q310-QTR) from $1,947 (Q309-QTR). The increase is directly related to sales volume increases as a result of our rollout of Cobroxin to the food and drug industry.

Selling and Marketing Costs - Selling and marketing costs increased $800,154 or 627.5%, to $927,676 (Q310-QTR) from $127,522 (Q309-QTR). The increase in selling and marketing expenses is primarily due to advertising and marketing expenses associated with the Cobroxin rollout.

General and Administrative Costs - General and administrative costs decreased ($117,441) or 46.6%, to $134,786 (Q310-QTR) from $252,229 (Q309-QTR). The decrease in general and administrative expenses is primarily related to reductions in compensation for consultants wherein the agreements have either been modified or terminated between 2009 and 2010.

Other Income(Expense) - Other income(expense) increased $56,767 or 135.4% to ($98,693) (Q310-QTR) from ($41,926) (Q309-QTR). The decrease in other expense is related to one time charges occurring in Q309-QTR that did not repeat in Q310-QTR.

Net Income(Loss) - Net income(loss) increased $241,386 or 57% to ($664,721) (Q310-QTR) from ($423,335) (Q309-QTR). The increase in net income(loss) is related to substantial advertising and marketing expense as our result of our efforts to establish the Cobroxin brand.

20

Comparison of the nine months ended September 30, 2010 (“Q310-YTD”) to the nine months ended September 30, 2009 (“Q309-YTD”)

Net Revenues - Total net revenues increased $2,284,341 or 2,858%, to $2,364,270 (Q310-YTD) from $79,929 (Q309-YTD). We began redirected our efforts and allocated available resources to concentrate on the marketing, promotion and distribution of Cobroxin in the third quarter of 2009. That initial effort was directed primarily to internet based marketing directly to consumers. During the fourth quarter of 2009 and on into the current quarter, we began phase two of our marketing strategy which expanded our focus to retailers in the food and drug industry. In the first quarter of 2010 we have added a significant number of retailers, cataloguers and drug chains as customers, as discussed above. Sales in Q309-YTD were primarily the result of our Clinical and Protective NSPs whereas sales in Q310-YTD were primarily from Homeopathic Medication products, specifically Cobroxin.

Cost of Revenues - Total cost of revenues increased $708,164 or 2,893.4%, to $732,639 (Q310-YTD) from $24,475 (Q309-YTD). The increase is directly related to sales volume increases as a result of our rollout of Cobroxin to the food and drug industry.

Selling and Marketing Costs - Selling and marketing costs increased $2,164,902 or 882%, to $2,410,362 (Q310-YTD) from $245,460 (Q309-YTD). The increase in selling and marketing expenses is primarily due to advertising and marketing expenses associated with the Cobroxin rollout. During the first three quarters of 2010, the Company has invested in magazine adds, promotion maters and media and sporting events and well as acquiring sponsorships and endorsements.

General and Administrative Costs - General and administrative costs decreased ($482,046) or 48.6%, to $477,785 (Q310-YTD) from $929,831 (Q309-YTD). The decrease in general and administrative expenses is primarily related to reductions in compensation for consultants wherein the agreements have either been modified or terminated between 2009 and 2010.

Other Income(Expense) - Other income(expense) increased $50410 or 35.1% to ($193,876) (Q310-YTD) from ($143,466) (Q309-YTD). The decrease in other expense is related to one time charges occurring in Q309-YTD that did not repeat in Q310-YTD.

Net Income(Loss) - Net income(loss) increased $177,048 or 13.8% to ($1,458,302) (Q310-YTD) from ($1,281,254) (Q309-YTD). The increase in net income(loss) is related to substantial advertising and marketing expense as our result of our efforts to establish the Cobroxin brand.

Liquidity and Capital Resources

Overview

We generated a net loss for the nine months ended September 30, 2010 of $1,458,302 and had a deficit in working capital of $1,385,500 at September 30, 2010. Our loss is primarily the result of our continuing investment in advertising to build the Cobroxin brand. We believe that we have achieved a successful launch of our Cobroxin product and that its acceptance in the market place will continue to expand. Although we have raised approximately $2,500,000 in capital to implement our Cobroxin launch, we understand that we will need even more capital to promote, acquire and support logistics as our market penetration expands. For these reasons, specifically, limited track record of profitability and continued demand for capital to implement our Cobroxin product strategy, our ability to continue as a going concern is still in doubt.

Based on our current plans, we anticipate that revenues earned from Cobroxin product sales will be the primary source of funds for operating activities. In addition to existing cash and cash equivalents, we may rely on bank borrowing, if available, or sales of securities to meet our capital and liquidity needs for the next 12 months. Additional capital may be sought to fund the expansion of our product line and marketing efforts, which may also include bank borrowing, or a private placement of securities.

We plan to continue utilizing our current resources to further develop our business, establish our sales and marketing network, operations, customer support and administrative organizations. We believe, based upon indications from our sales agents and others that sufficient revenues will continue to be generated from product sales to cover our expenses. These revenues from product sales together with proceeds from private fundings should be sufficient to meet presently anticipated working capital and capital expenditure requirements over the next 12 months. To the extent that we do not generate sufficient revenues we will reduce our expenses and/or seek additional financing. As of September 30, 2010 there were no commitments for long-term capital expenditures other than those discussed in Note 7 to the quarterly financial statements.

21

Cash Flows for the Nine months ended September 30, 2010.

Our cash and cash equivalents decreased $216,536 to $8,483 as of September 30, 2010 from $225,019 as of December 31, 2009.

Cash Flows from Operating Activities

Operating activities used net cash for the nine months ended September 30, 2010 of $2,757,213. Net cash used resulted from a net loss of approximately $1,457,052, after adjustment for various items which impact net income but do not impact cash during the period, such as depreciation and stock issued for services. In addition, cash used in operating activities also reflected net cash used from a net change in working capital components of $1,285,161. The most significant working capital component changes were an increase in inventory of $642,357, resulting from increasing inventory to support increasing Cobroxin sales; an increase in accounts receivable of $535,226also as a result of increased sales and an increase in prepaid expenses of $432,188. These uses of cash were partially funded by vendors through an increase in accounts payable of $122,209.

Cash Flows used in Investing Activities

Our investing activities used $21,472 in net cash during the nine months ended September 30, 2010, for a lease deposit on our new corporate headquarters and the purchase of additional computers and office equipment.

Cash Flows from Financing Activities

Our financing activities provided net cash of $2,547,149 for the nine months ended September 30, 2010. We raised approximately $2,554,149 in advances from a shareholder in the form of a note. We also repaid $57,000 in advances from certain officers and received $50,000 for the sale of common shares.

Financial Position

Our total assets increased $1,413,455 to $2,942,802 as of September 30, 2010 from $1,529,347 as of December 31, 2009.

Most of the increase, $1,393,233 or 98.6% was from changes in our current assets which are described above in the discussion of cash flows from operating activities as it relates to net changes in working capital components. The remainder of the increase resulted from changes in long term assets primarily associated with a rent deposit for our new corporate headquarters and the purchase of additional equipment.

Borrowings Outstanding

As of September 30, 2010, we had borrowings of $3,154,038, which are discussed more fully in Note 6. However, most of our financing has come from private sources who are also shareholders in the Company. We also obtained financing from a potential merger partner, specifically $977,000 from Sun Packing, Inc. also discussed in Note 6. We do have a $10,000 available credit line from Wachovia which was intended to establish a commercial banking relationship, however given its limit, we currently consider this facility to be nominal.

During the third quarter of 2010 the Company entered into a factoring agreement covering certain of its accounts receivable. The agreement provides for factoring at 85% of its face value and collection is subject to recourse. As of September 30, 2010, the Company had borrowings of $173,861 outstanding under the factoring agreement.

Material Commitments, Expenditures and Contingencies

We had no outstanding purchase commitments to purchase raw materials as of September 30, 2010. Our distribution and marketing agreement with the manufacturer of Cobroxin contains certain performance criteria, which the Company has satisfied. We believe that a minimum of an additional $1,000,000 will be needed over the next 3 months to continue the successful launch of the Cobroxin product based on purchase orders and commitments received.

Dividends

We have not paid any dividends.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The rules applicable to a smaller reporting company do not require further disclosure in this item.

22

ITEM 4.

CONTROLS AND PROCEDURES

As of September 30, 2010, and as of the date of this report, our board of directors does not currently have any independent members; furthermore, no director qualifies as an audit committee financial expert as defined in Item 407(d)(5)(ii) of Regulation S-B.

23

PART II – OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS

None

ITEM 1A.

RISK FACTORS

There have been no material changes during the period ended September 30, 2010 in our risk factors as set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2009.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Common Stock – note – Don’t need to repeat sales previously reported and should be limited to Sept. quarter.

Add 1,600,000 shares issued in Sept. quarter as disclosed in Note 8?

In June we sold 312,500 shares of our common stock to an accredited investor for $50,000. No broker dealer was involved in the sale of the shares and no commissions or other remuneration was paid in connection with the sale. The shares were issued in a private placement to an accredited investor pursuant to an exemption from registration under the Securities Act of 1933 pursuant to Section 4(2) thereof and Rule 506 of Regulation D. The shareholder who received the forgoing shares signed a subscription agreement acknowledging that the shares were not registered under the Securities Act of 1933, and could only be sold under a registration or exemption from registration. Each certificate for such shares contains a restrictive legend concerning the foregoing restrictions on transfer and a stop transfer order has been lodged against such shares. The investor was offered access to our books and records and the opportunity to ask our officers questions and receive answers concerning the terms and condition of the offering and the company.

Preferred Stock

During the first quarter of 2010, all accrued and unpaid compensation and benefits for two consultants, one who provided acquisition and financing services and one who provided administration services, totaling $536,918 were converted into 53,686 Series E preferred shares. There services were terminated in 2009 and no new agreements were entered into with these individuals.

During the first quarter of 2010, $1,000,000 of outstanding debt was converted into 100,000 shares of Series E preferred shares.

During the first quarter of 2010, two employees (the CFO and the President) who are lenders to the Company converted $346,487 of their outstanding debt into 34,639 shares of Series E preferred stock.

No broker dealer was involved in the sale of the shares and no commissions or other remuneration were paid in connection with the sale. The shares were issued in a private placement to an accredited investor pursuant to an exemption from registration under the Securities Act of 1933 pursuant to Section 4(2) thereof and Rule 506 of Regulation D. The shareholder who received the forgoing shares signed a subscription agreement acknowledging that the shares were not registered under the Securities Act of 1933, and could only be sold under a registration or exemption from registration. Each certificate for such shares contains a restrictive legend concerning the foregoing restrictions on transfer and a stop transfer order has been lodged against such shares. The investor was offered access to our books and records and the opportunity to ask our officers questions and receive answers concerning the terms and condition of the offering and the company.

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4.

(REMOVED AND RESERVED)

ITEM 5.

OTHER INFORMATION

None

24

ITEM 6.

EXHIBITS

No.	Description
31.1	Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act.
31.2	Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act.
32.1	Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act.
32.2	Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act.

25

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: November 15, 2010

XENACARE HOLDINGS, INC.
By:	/s/ FRANK RIZZO
	Frank Rizzo
	President (principal executive officer) and Director
By:	/s/ BOBBY STORY
	Bobby Story
	Chief Financial Officer and Treasurer (principal financial and accounting officer)

26